MARKET

TBPH

TBPH

Theravance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.11
+0.25
+3.64%
After Hours: 7.20 +0.09 +1.27% 18:57 09/17 EDT
OPEN
6.86
PREV CLOSE
6.86
HIGH
7.27
LOW
6.77
VOLUME
2.80M
TURNOVER
--
52 WEEK HIGH
22.74
52 WEEK LOW
6.10
MARKET CAP
522.37M
P/E (TTM)
-1.7284
1D
5D
1M
3M
1Y
5Y
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
Zacks · 14h ago
Analyst Ratings For Theravance Biopharma
Analysts have provided the following ratings for Theravance Biopharma (NASDAQ:TBPH) within the last quarter:
Benzinga · 1d ago
Theravance (TBPH) to Cut Workforce, Hypotension Study Fails
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.
Zacks · 1d ago
Morgan Stanley Maintains Underweight on Theravance Biopharma, Lowers Price Target to $10
Morgan Stanley analyst Vikram Purohit maintains Theravance Biopharma (NASDAQ:TBPH) with a Underweight and lowers the price target from $14 to $10.
Benzinga · 1d ago
HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $8
HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $21 to $8.
Benzinga · 1d ago
SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $10
SVB Leerink analyst Geoffrey Porges maintains Theravance Biopharma (NASDAQ:TBPH) with a Outperform and lowers the price target from $29 to $10.
Benzinga · 1d ago
Needham Downgrades Theravance Biopharma to Hold From Buy
MT Newswires · 1d ago
Baird Adjusts Theravance Biopharma PT to $7 From $10, Maintains Neutral Rating
MT Newswires · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBPH. Analyze the recent business situations of Theravance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBPH stock price target is 9.38 with a high estimate of 14.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 161
Institutional Holdings: 80.04M
% Owned: 108.94%
Shares Outstanding: 73.47M
TypeInstitutionsShares
Increased
41
6.71M
New
20
3.62M
Decreased
25
2.63M
Sold Out
18
368.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Director
Rick Winningham
Chief Financial Officer/Senior Vice President
Andrew Hindman
Corporate Executive
Ann Brady
Executive Vice President/General Counsel/Secretary
Bradford Shafer
Senior Vice President
Richard Graham
Senior Vice President
Frank Pasqualone
Senior Vice President
Kenneth Pitzer
Senior Vice President
Vijay Sabesan
Senior Vice President
Philip Worboys
Lead Director/Independent Director
William Young
Independent Director
Laurie Alsup
Independent Director
Eran Broshy
Independent Director
Burton Malkiel
Independent Director
Dean Mitchell
Independent Director
Susan Molineaux
Independent Director
Donal O'Connor
Independent Director
Deepika Pakianathan
No Data
About TBPH
Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.